ARQT vs RMD · rev $235.3M vs P/E 29, rev $5.65B
Arcutis Biotherapeutics Inc (ARQT) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
ARQT currently screens at market cap $1.64B. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the ARQT and RMD stock pages for the full models.
Not investment advice.